Quick Answer
aTYR PHARMA INC reported Cash and Equivalents of $10.74 million for fiscal year 2025.
aTYR PHARMA INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $10.74M | -2.8% |
| 2024 | $11.05M | -51.0% |
| 2023 | $22.54M | +125.9% |
| 2022 | $9.98M | +327.3% |
| 2021 | $2.34M | -86.2% |
| 2020 | $16.95M | +84.1% |
| 2019 | $9.21M | -59.9% |
| 2018 | $22.96M | +8.9% |
| 2017 | $21.09M | -45.1% |
| 2016 | $38.39M | -27.6% |
| 2015 | $53.02M | +281.5% |
| 2014 | $13.90M | -61.9% |
| 2013 | $36.46M | +892.0% |
| 2012 | $3.67M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.15M | -46.3% | -64.3% |
| June 30, 2025 | $17.22M | +153.0% | +66.2% |
| March 31, 2025 | $10.36M | +52.2% | -6.3% |
| December 31, 2024 | $11.05M | -51.0% | -3.5% |
| September 30, 2024 | $11.46M | +17.1% | +68.4% |
| June 30, 2024 | $6.80M | -44.7% | -0.0% |
| March 31, 2024 | $6.81M | -67.1% | -69.8% |
| December 31, 2023 | $22.54M | +125.9% | +130.3% |
- aTYR PHARMA INC showed a decrease of -2.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, aTYR PHARMA INC’s cash and equivalents has grown by 192.3% (from $3.67 million to $10.74 million).
- The most recent figure is from aTYR PHARMA INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: